http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S6399017-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2d15a4a3ede0e6e55194a1679d68c89e |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-675 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-27 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K33-24 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00 |
| filingDate | 1986-11-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_38d29fe273f084b206e849040aa0cb90 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_08e41d2f867a591295173af8e65511f0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fe83962af2f9222432661ea7d2de457 |
| publicationDate | 1988-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-S6399017-A |
| titleOfInvention | Carcinostatic action regulator |
| abstract | PURPOSE: To obtain the titled regulator, containing a growth factor and a peptide corresponding to part of constituent ingredients thereof as an active ingredient and capable of enhancing the anticancer actin of a compound having the anticancer action and relieving side effects thereof. n CONSTITUTION: An anticancer action regulator containing a growth factor such as epithelial cell growth factor group, e.g. human epithelial cell growth factor (hEGF), insulin group, blood platelet-derived growth factor group, e.g. fibroblastic growth factor, etc., and a peptide corresponding to part of constituent ingredients thereof, derivative or salt thereof as an active ingredient. A derivative in which methionine at the 21st residue from the N-terminal is converted into leucine in 53 amino acid residues constituting the hEGF, two of leucine and arginine deficient in the C-terminal, etc., are cited as the above- mentioned derivative. The dose of the above-mentioned regulator is preferably about 10ngW10mg expressed in terms of the growth factor, etc., a day for an adult and the regulator is also effectively used as a radiosensitizer in radiotherapy. n COPYRIGHT: (C)1988,JPO&Japio |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H05294994-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-S63107941-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2181704-A2 |
| priorityDate | 1985-11-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 116.